David RP Almeida MD MBA PhD
Dr. David R.P. Almeida, MD, MBA, PhD, FRCSC, DABO, serves as Executive Chairman of Erie Retina Research. A distinguished vitreoretinal surgeon and healthcare innovator, he has transformed Erie Retina Research into a leading clinical research organization in ophthalmology. He manages over 52 active trials across nine international sites with a perfect FDA audit success rate.
As the founder of The Centers for Advanced Surgical Exploration (CASEx) and READ AI Digital, David leads a revolutionary healthcare platform with tremendous year-over-year growth. His innovative AI-powered clinical trial platform has demonstrated consistent success in reducing trial timelines by 40% while generating over $100M in savings per drug development cycle.
David’s academic credentials include an Honors Bachelor of Science from the University of Toronto, a PhD in pharmaceutical research from the University of Szeged (graduated Summa cum Laude), and an MBA in healthcare management from The George Washington University. His clinical training includes medical school and an ophthalmology residency at Queen’s University, followed by a vitreoretinal diseases and surgery fellowship at the University of Iowa.
A prolific researcher and innovator, David has spearheaded the development of several successful ventures, including CLINOMICS.ai and PAX IMPACT SOLUTIONS. His strategic partnerships with major institutions like Stanford University and global corporations demonstrate his ability to build and scale healthcare enterprises.
David is internationally recognized as a thought leader in ophthalmology, with over 300 peer-reviewed publications and more than 125 conference presentations. His achievements have been recognized with numerous awards, including the American Society of Retina Specialists (ASRS) Honor Award and inclusion in The Ophthalmologist Power List Top 50 Rising Stars in Ophthalmology.
Beyond his corporate leadership, David’s unique combination of clinical expertise, research acumen, and business insight positions him ideally to lead the continued growth and innovation in AI-powered healthcare & clinical research delivery.
